مباشر
CellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvationCellReplaying germinal center evolution on a quantified affinity landscapeCellXenophagocytosis blockade enhances interspecies chimerismFierceBiotechADA: Pfizer pads case for berobenatide in obesity, adding validation to Metsera buyEndpoints News#ADA26: Pfizer monthly shot shows effect on obesity, diabetesEndpoints News#ADA26: Roche to start Phase 2 petrelintide, enicepatide combo trial this yearEndpoints NewsLawmakers propose China restrictions; #ASCO26 recap; and moreFierceBiotech‘It looks like this hypothesis will pan out’: Cullinan unveils data building case for autoimmune TCEsEndpoints News#ADA26: Roche incretin shot works in mid-stage trial in type 1 diabetesClinical OMICsBlood-Based Risk Score Could Enable Earlier Lung Cancer PreventionClinical OMICsMicroglial State Shift May Determine Whether Alzheimer’s Disease Pathology Leads to DementiaEndpoints NewsIn Washington, biotech's China hawks are winning the conversation
FierceBiotech ١٨ فبراير ٢٠٢٦

Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study

Lilly pays CSL $100M upfront for IL-6 antibody that flunked a phase 3 organ transplant study

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.